Background: Patients with mild cognitive impairment (MCI) and dementia due to Alzheimer’s disease show a pattern of “slowing” on resting state electroencephalography (EEG), often indexed by ratio of theta to beta power. The objective of this study was to investigate associations between theta/beta power ratio, subjective cognitive decline, and cognitive reserve in cognitively unimpaired older adults at high versus low risk for AD.
Method: Cognitively unimpaired older adults at high risk (4 carrier and positive family history; N = 25) or low risk ( non‐4 carrier and negative family history; N = 25) for AD completed questionnaires about subjective cognitive decline (SCD; Everyday Cognition Scale) and cognitive reserve (Cognitive Reserve Index Questionnaire). Five minutes of eyes‐open 64‐channel resting state EEG was acquired. Data were separated into 2s epochs for analysis, and ratio of theta to beta power at left (F3, F5, F7), mid (Fz, FCz, Cz), and right (F4, F6, F8) frontal electrodes was calculated.
Result: After controlling for age, there was a significant positive association between cognitive reserve index and theta/beta power across left, right, and midfrontal regions (all ’s > .30, ’s < .03). The magnitude of these associations did not differ between people at high versus low risk for AD. However, only the high‐risk group showed a significant positive association between higher right and left frontal theta/beta ratio and greater SCD symptoms (’s > .4, ’s < .05).
Conclusion: A pattern of EEG slowing (higher theta/beta ratio) was associated with greater SCD selectively in those at high risk for AD. Interestingly, increased EEG slowing was also associated with greater cognitive reserve in cognitively unimpaired older adults. One potential explanation for these findings is that people with higher cognitive reserve are able to maintain a cognitively unimpaired state despite the presence of AD‐related EEG slowing while those with lower cognitive reserve cannot; however, biomarker studies are needed to clarify.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/alz.095513 | DOI Listing |
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11712468 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Associations between lifelong cognitive reserve, Alzheimer's disease-related plasma biomarkers, and cognitive function in dementia-free older adults: A population-based study.
J Alzheimers Dis
January 2025
Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, P.R. China.
Background: Cognitive reserve (CR), typically measured through socio-behavioral proxies, can partially explain better cognitive performance despite underlying brain aging or neuropathology.
Objective: To examine the associations of CR with mild cognitive impairment (MCI) and cognitive function while considering Alzheimer's disease (AD)-related plasma biomarkers.
Methods: This population-based cross-sectional study included 4706 dementia-free individuals from MIND-China.
Clinical performance of plasma P‐tau217 for the identification of primary Alzheimer’s disease pathology or co‐pathology in sporadic frontotemporal dementia.
Alzheimers Dement
December 2024
University of California San Francisco (UCSF), San Francisco, CA, USA
Background: As new anti‐amyloid immunotherapies emerge for Alzheimer’s disease (AD), it is clear that early diagnosis of AD pathology is crucial for treatment success. This can be challenging in atypical presentations of AD and, together with our reliance on CSF or PET scans, can, at times, lead to delayed diagnosis. Here, we further explore the possible role of plasma tau phosphorylated at threonine 217 (P‐tau217) for the detection of primary AD or AD co‐pathology when frontotemporal dementia spectrum disorders are the main clinical presentation.
View Article and Find Full Text PDFBackground: Alzheimer’s disease (AD) is defined by the accumulation of Aβ plaques and tau neurofibrillary tangles. The consequences of these pathologies include neurodegeneration and cognitive dysfunction. However, the process by which AD pathologies leads to cognitive impairment remains unclear.
View Article and Find Full Text PDFInfluence of biological sex on early cognitive performance in FTLD mutation carriers: an ALLFTD study.
Alzheimers Dement
December 2024
Hospital de la Santa Creu i Sant Pau, Barcelona, Barcelona, Spain
Background: Accumulating evidence indicates that biological sex may influence clinical manifestation within the spectrum of frontotemporal lobar degeneration (FTLD), implying differences in cognitive reserve. Nonetheless, investigations into the impact of biological sex during the preclinical and minimally symptomatic stages of FTLD are lacking.
Method: We included 275 mutation carriers (158 females; 127 with C9orf72, 68 with GRN, and 80 with MAPT mutations) and 161 non‐carrier familial controls (97 females) from the ALLFTD Consortium (Staffaroni et al.
Examining early cerebral amyloid beta and tau accumulation in association with cognition in a predominantly middle‐aged cohort.
Alzheimers Dement
December 2024
The Framingham Heart Study, Framingham, MA, USA
Background: In older adults, greater amyloid (Aβ) and tau positron emission tomography (PET) binding is associated with cognitive decline and dementia. However, the association of early amyloid and tau PET accumulation with cognition at midlife remains unclear. The goal of the current study was to evaluate the associations of Aβ and tau PET with cognition in a predominately middle‐aged community‐based cohort, as well as to examine the factors that may modify these associations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!